Anavex Life Sciences Corp (AVXL)

[falconer66a]

A Conjecture: Selection of Those Vulnerable to Alzheimer’s

A study just published tells of ways to assess vulnerabilities to ensuing Alzheimer’s:

Two groups of interest emerged -- those whose cognition declined significantly and those who saw little or no decline in their symptoms. The brain scans of the 240 so-called 'rapid decliners' showed twice the rate of atrophy as the 184 people with a slow-moving disease. Rapid decliners also progressed from mild cognitive impairment to dementia at five times the rate of those with slow-moving disease, the analysis showed.
The team went further to devise a simpler way scientists could identify these two distinct groups in future research using existing paper-and-pencil cognitive tests.
Researchers could use these findings to create more homogeneous trial groups, which would allow scientists to design shorter trials and gain better insights on the effectiveness of experimental therapies, Gamberger said.

https://www.eurekalert.org/pub_releases/2017-07/dumc-sun072617.php

After Anavex 2-73 gains FDA approval and is in medical use, middle-aged folks who are starting to forget where they left their keys or why they walking into a room can have their physician (well, the nurse) run one of these tests. If positive, the fortunate fellow would be put on Anavex 2-73, to prevent the onset of the predicted Alzheimer’s he would have otherwise suffered.

Alzheimer’s prophylaxis. Another profound personal, social, and economic benefit of Anavex Life Sciences Corp (sometime in the future, of course).

Perhaps, right now, Anavex Life Sciences could use these new tests to select a Phase 3 trial population of true “rapid decliners,” people who really had debilitating Alzheimer’s.